15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Syndax Pharmaceuticals Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $33.00 to $57.00, a moderate spread. The average target of $42.20 sits 112% above the current $19.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-0.82 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Syndax Pharmaceuticals Inc.
As of Sep, 9 of 9 firms rate SNDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SNDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.60 – $-0.27 · 10 analysts · -45% YoY
Next period, 10 analysts expect Syndax Pharmaceuticals Inc to earn $-0.43 a share (range $-0.60 – $-0.27), versus $-0.78 a year earlier. Full-year consensus is $-1.93, growing to $-0.82 the year after.
REVENUE · NEXT QUARTER
$97.0M
Range $86.9M – $127.9M · 10 analysts · +41% YoY
Revenue is expected to reach $97.0M (range $86.9M – $127.9M), +41.2% year-over-year. Full-year consensus is $316.1M, rising to $463.1M next year.
Top analysts covering Syndax Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNDX.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$32.00+60.4% to target
Overall win rate
55%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$33.00+65.4% to target
Overall win rate
50%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #75
Buy
$40.00+100.5% to target
Overall win rate
51%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$38.00+90.5% to target
Overall win rate
39%
+ Follow
#5
George Farmer
Scotiabank · Rank #240
Hold
$17.00-14.8% to target
Overall win rate
44%
+ Follow
SNDX stock forecast FAQ
What is SNDX's average 12-month price target?+
The 10 analysts with a live target average $42.20 for Syndax Pharmaceuticals Inc over the next 12 months, ranging from a $57.00 high to a $33.00 low.
Is SNDX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SNDX?+
The Street-high target is $57.00 (Citigroup), and the Street-low is $33.00 (UBS). The average of all 10 active targets is $42.20.
How many Wall Street analysts cover SNDX?+
10 analysts have an active rating on Syndax Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering SNDX?+
Among analysts who currently cover SNDX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $32.00 target.
What is Syndax Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.60 – $-0.27) across 10 analysts. Full-year EPS is projected at $-1.93, rising to $-0.82 the following year.
How much revenue is Syndax Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $97.0M (range $86.9M – $127.9M). Full-year revenue is projected at $316.1M, growing to $463.1M next year.
Have analysts been upgrading or downgrading SNDX lately?+
As of Sep, 9 of 9 firms rate SNDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
